Aprepitant for itching from immunotherapy in solid cancers
Part of Skin clinical trials.
This trial tests whether a medicine called aprepitant can reduce itching caused by immunotherapy drugs in people with solid tumors. If you have bothersome itching that won't go away, this treatment might help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor (for example, melanoma, kidney cancer, or lung cancer).
- You must be currently receiving an immunotherapy drug, like nivolumab, pembrolizumab, or ipilimumab.
- You must have itching that is either not controlled by standard treatments or started after beginning immunotherapy.
- You must be able to care for yourself and be up and about at least half of the day (ECOG 0–2).
- You must not be pregnant or breastfeeding, and you must not have had a severe allergic reaction to aprepitant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two oral medications, methotrexate and apremilast, to see which works better at reducing itching in people with psoriasis. You might join to help find a more effective way to relieve itch.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study tests whether a cannabis-based oral spray (with equal parts THC and CBD) can safely reduce severe itching when other treatments haven't helped. It compares the spray to an inactive placebo to see if it truly works.
This trial tests a gel called TriCalm Hydrogel to see if it helps reduce itching caused by immunotherapy cancer treatment. If you have itching from your immunotherapy, this study might offer relief.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.